Table 3.
Incidence of the primary and secondary efficacy outcomes stratified by trial group
| Outcome | Total n=131 |
Intervention n=66 |
Control n=65 |
OR (95% CI),p value | |
| Early discharge within 4 hour without prevalent AMI or incident MACE at 30 days, n (% (95% CI)) |
22 (17%) | 17 (26%) | 5 (8%) | Unadjusted Adjusted* |
4.16 (1.43 to 12.09), p0.009 5.45 (1.73 to 17.11), p=0.004 |
| Prevalent AMI, n (%) | 9 (7) | 3 (5) | 6 (9) | 0.47 (0.11 to 1.96), p=0.30 | |
| Incident MACE at 30 days†, n (%) | 6 (5) | 3 (5) | 3 (5) | 0.98 (0.19 to 5.06), p=0.985 | |
| Incident MACE at 90 days†, n (%) | 9 (7) | 5 (8) | 4 (6) | 1.36 (0.35 to 5.34), p=0.656 | |
| Incident MACE at 180 days†, n (%) | 11 (8) | 6 (9) | 5 (8) | 1.30 (0.37 to4.56), p=0.678 | |
| Hospital length of stay (median, IQR) | 1 (0–1) | 1 (0–1) | 1 (0–1) | p=0.54‡ | |
| Patient satisfaction (mean score, SD) | 3.8 (1.0) | 3.8 (1.0) | 3.8 (1.1) | p=0.80‡ | |
| Re-attendance at an ED, n (%) | 18 (23) | 10 (23) | 8 (23) | p=0.97 | |
| Any further investigation for heart disease within 30 days, n (%) | 27 (21) | 15 (23) | 12 (18) | p=0.55 | |
| Myocardial perfusion imaging (thallium scan) within 30 days, n (%) | 8 (28) | 3 (19) | 5 (38) | p=0.24 | |
| Stress ECG within 30 days, n (%) | 1 (4) | 1 (7) | 0 (0) | p=0.34 | |
| Coronary angiography within 30 days, n (%) | 9 (32) | 4 (27) | 5 (38) | p=0.51 |
*Adjusted for trial centre, age, gender, cardiovascular risk factors and history of prior coronary artery disease. This is the prespecified primary analysis.
†Incident death, AMI or coronary revascularisation (not including prevalent AMI). NB, no patients who were discharged early developed a MACE.
‡Mann-Whitney U test.
MACE, major adverse cardiac event.